S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

$2.40
+0.21 (+9.59%)
(As of 03/28/2024 ET)
Today's Range
$2.13
$2.47
50-Day Range
$1.30
$3.58
52-Week Range
$0.92
$3.79
Volume
7.06 million shs
Average Volume
5.01 million shs
Market Capitalization
$590.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Lexicon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
108.3% Upside
$5.00 Price Target
Short Interest
Bearish
8.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Lexicon Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to ($0.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.48 out of 5 stars

Medical Sector

897th out of 939 stocks

Pharmaceutical Preparations Industry

422nd out of 444 stocks

LXRX stock logo

About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

LXRX Stock Price History

LXRX Stock News Headlines

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 5.8%
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
LXRX Apr 2024 5.000 put
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Lexicon: Q4 Earnings Snapshot
Lexicon Pharmaceuticals: Q4 Earnings Insights
15 Hot Penny Stocks On the Move
LXRX Feb 2024 5.000 put
MSCLF: AAK1 Disclosed as Drug Target for DMD Program…
The Woodlands at 50
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/29/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
135
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+108.3%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-175,610,000.00
Net Margins
-14,573.20%
Pretax Margin
-14,710.88%

Debt

Sales & Book Value

Annual Sales
$1.20 million
Book Value
$0.62 per share

Miscellaneous

Free Float
228,270,000
Market Cap
$590.98 million
Optionable
Optionable
Beta
1.28

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Lonnel Coats (Age 59)
    CEO & Director
    Comp: $1.22M
  • Mr. Jeffrey L. Wade J.D. (Age 59)
    President & CFO
    Comp: $788.65k
  • Mr. Brian T. Crum (Age 50)
    Senior VP, General Counsel & Secretary
    Comp: $609.1k
  • Dr. Kenneth B. Kassler-Taub M.D. (Age 67)
    Senior Vice President of Regulatory Affairs & Quality Assurance
    Comp: $588.7k
  • Dr. Craig B. Granowitz M.D. (Age 58)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $671.14k
  • Dr. Robert J. Lefkowitz M.D. (Age 80)
    Consultant & Independent Director
    Comp: $50k
  • Ms. Kristen L. Alexander (Age 55)
    Vice President of Finance & Accounting
  • Ms. Lisa M. DeFrancesco (Age 44)
    Head of Investor Relations & Corporate Strategy
  • Chas Schultz
    Executive Director of Corporate Communications & Patient Advocacy
  • Ms. Wendy E. McDermott (Age 52)
    Vice President of Human Resources

LXRX Stock Analysis - Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock price target for 2024?

0 Wall Street research analysts have issued 1-year target prices for Lexicon Pharmaceuticals' stock. Their LXRX share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2024?

Lexicon Pharmaceuticals' stock was trading at $1.53 at the beginning of the year. Since then, LXRX shares have increased by 56.9% and is now trading at $2.40.
View the best growth stocks for 2024 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 138.54% and a negative net margin of 14,573.20%. During the same period in the prior year, the business earned $0.71 earnings per share.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.98%), Vanguard Group Inc. (2.44%), Vanguard Group Inc. (2.44%), Pinnacle Associates Ltd. (0.71%), Charles Schwab Investment Management Inc. (0.35%) and Northern Trust Corp (0.35%). Insiders that own company stock include International SCA Artal, Jeffrey L Wade, Lonnel Coats, Raymond Debbane and Wendy Mcdermott.
View institutional ownership trends
.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LXRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners